Aurinia Pharmaceuticals Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001600620-26-000049
- Form type
- 10-Q
- CIK
- 0001600620
- Primary document
- https://www.sec.gov/Archives/edgar/data/1600620/000160062026000049/auph-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Aurinia Pharmaceuticals Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $77.7M | - | - |
| Cost Of Revenue | $6.5M | - | - |
| Operating Income | $41.4M | - | - |
| Net Income | $34.4M | - | - |
| Eps Basic | 0.26 | - | - |
| Eps Diluted | 0.25 | - | - |
| Cash And Equivalents | $40.7M | - | - |
| Total Assets | $724.0M | - | - |
| Total Liabilities | $156.4M | - | - |
| Shareholders Equity | $567.6M | - | - |
| Operating Cash Flow | $32.6M | - | - |